Treace Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

PONTE VEDRA, Fla., Oct. 25, 2022 – Treace Medical Concepts, Inc. (TMCI), a leader in bunion surgical treatment, announced participation in two upcoming investor conferences. CEO John T. Treace and CFO Mark L. Hair will represent the company at the J.P. Morgan Equity Opportunities Forum on November 14, 2022, and at the Stifel 2022 Healthcare Conference on November 15, 2022. The latter will feature a fireside chat at 9:10 AM ET, accessible via the company’s investor relations website. Treace aims to revolutionize bunion surgery with its patented Lapiplasty® system, targeting 1.1 million surgical candidates in the U.S.

PONTE VEDRA, Fla., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in the following upcoming investor conferences.

• The J.P. Morgan Equity Opportunities Forum on Monday, November 14, 2022; and
• The Stifel 2022 Healthcare Conference on Tuesday, November 15, 2022, with a fireside chat at 9:10am ET.

A live webcast and replay of the fireside chat will be available on the Company’s investor relations website at https://investors.treace.com/.

About Treace Medical Concepts 
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 65 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction™ system – a combination of instruments, implants, and surgical methods designed to surgically correct all 3 planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. Treace recently expanded its offering with the Adductoplasty™ Midfoot Correction System, designed for reproducible surgical correction of the midfoot to provide further support to hallux valgus patients. For more information, please visit www.treace.com.

Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.com
(904) 373-5940

Investors:
Gilmartin Group
Lynn Lewis or Vivian Cervantes
IR@treace.com

 

FAQ

What investor conferences will TMCI participate in?

Treace Medical Concepts, Inc. (TMCI) will participate in the J.P. Morgan Equity Opportunities Forum on November 14, 2022, and the Stifel 2022 Healthcare Conference on November 15, 2022.

When is the fireside chat scheduled for TMCI?

The fireside chat for Treace Medical Concepts (TMCI) is scheduled for November 15, 2022, at 9:10 AM ET during the Stifel 2022 Healthcare Conference.

How can I access TMCI's fireside chat?

You can access the live webcast and replay of Treace Medical Concepts' (TMCI) fireside chat on the company's investor relations website.

What is the focus of Treace Medical Concepts?

Treace Medical Concepts, Inc. (TMCI) specializes in the surgical treatment of bunions and has developed the Lapiplasty® 3D Bunion Correction™ system to address this condition.

How many Americans are surgical candidates for bunion treatment according to TMCI?

Treace Medical Concepts estimates that approximately 1.1 million Americans are annual surgical candidates for bunion treatments.